TY  - JOUR
AU  - Pei, Yanxin
AU  - Liu, Kun-Wei
AU  - Wang, Jun
AU  - Garancher, Alexandra
AU  - Tao, Ran
AU  - Esparza, Lourdes A
AU  - Maier, Donna L
AU  - Udaka, Yoko T
AU  - Murad, Najiba
AU  - Morrissy, Sorana
AU  - Seker-Cin, Huriye
AU  - Brabetz, Sebastian
AU  - Qi, Lin
AU  - Kogiso, Mari
AU  - Schubert, Simone
AU  - Olson, James M
AU  - Cho, Yoon-Jae
AU  - Li, Xiao-Nan
AU  - Crawford, John R
AU  - Levy, Michael L
AU  - Kool, Marcel
AU  - Pfister, Stefan
AU  - Taylor, Michael D
AU  - Wechsler-Reya, Robert J
TI  - HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
JO  - Cancer cell
VL  - 29
IS  - 3
SN  - 1535-6108
CY  - Cambridge, Mass.
PB  - Cell Press
M1  - DKFZ-2017-05383
SP  - 311 - 323
PY  - 2016
AB  - Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
KW  - Forkhead Transcription Factors (NLM Chemicals)
KW  - Histone Deacetylase Inhibitors (NLM Chemicals)
KW  - Proto-Oncogene Proteins c-myc (NLM Chemicals)
KW  - Phosphatidylinositol 3-Kinases (NLM Chemicals)
KW  - Histone Deacetylases (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26977882
C2  - pmc:PMC4794752
DO  - DOI:10.1016/j.ccell.2016.02.011
UR  - https://inrepo02.dkfz.de/record/130304
ER  -